

HARVARD BIOSCIENCE INC

Form 10-Q

November 05, 2010

[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 10-Q**

x **Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
For the quarterly period ended September 30, 2010

.. **Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 001-33957

**HARVARD BIOSCIENCE, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

<b>Delaware</b> (State or Other Jurisdiction of Incorporation or Organization)	<b>04-3306140</b> (IRS Employer Identification No.)
<b>84 October Hill Road, Holliston, MA</b> (Address of Principal Executive Offices)	<b>01746</b> (Zip Code)
<b>(508) 893-8999</b> (Registrant's telephone number, including area code)	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES  NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input checked="" type="checkbox"/>
Non-accelerated filer <input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES  NO

**APPLICABLE ONLY TO CORPORATE ISSUERS:**

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of November 1, 2010, there were 28,285,675 shares of Common Stock, par value \$0.01 per share, outstanding.

**Table of Contents**

**HARVARD BIOSCIENCE, INC.**

**Form 10-Q**

**For the Quarter Ended September 30, 2010**

**INDEX**

	<b>Page</b>
<b><u>PART I-FINANCIAL INFORMATION</u></b>	<b>3</b>
Item 1. <u>Financial Statements</u>	3
<u>Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009 (unaudited)</u>	3
<u>Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2010 and 2009 (unaudited)</u>	4
<u>Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2010 and 2009 (unaudited)</u>	5
<u>Notes to Unaudited Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	14
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	25
Item 4. <u>Controls and Procedures</u>	25
<b><u>PART II-OTHER INFORMATION</u></b>	<b>26</b>
Item 1A. <u>Risk Factors</u>	26
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	26
Item 6. <u>Exhibits</u>	26
<b><u>SIGNATURES</u></b>	<b>27</b>

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.****HARVARD BIOSCIENCE, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS****(unaudited, in thousands, except share and per share amounts)**

	September 30, 2010	December 31, 2009
<b><u>Assets</u></b>		
Current assets:		
Cash and cash equivalents	\$ 17,217	\$ 16,588
Accounts receivable, net of allowance for doubtful accounts of \$381 and \$403, respectively	13,837	14,383
Inventories	16,272	14,406
Deferred income tax assets - current	2,957	573
Other receivables and other assets	2,905	2,249
Total current assets	53,188	48,199
Property, plant and equipment, net	3,255	3,545
Deferred income tax assets - non-current	7,089	318
Amortizable intangible assets, net	20,444	21,104
Goodwill	34,642	32,108
Other indefinite lived intangible assets	1,285	1,301
Other assets	441	656
Total assets	\$ 120,344	\$ 107,231
<b><u>Liabilities and Stockholders' Equity</u></b>		
Current liabilities:		
Notes payable	\$ 3	\$ 13
Accounts payable	4,734	4,856
Deferred revenue	409	434
Accrued income taxes payable	509	369
Accrued expenses	3,917	3,680
Other liabilities - current	235	2,906
Total current liabilities	9,807	12,258
Long-term debt, less current installments	18,009	13,308
Deferred income tax liabilities - non-current	135	2,037
Other liabilities - non-current	3,961	4,371
Total liabilities	31,912	31,974
Commitments and contingencies		

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Stockholders' equity:

Preferred stock, par value \$0.01 per share, 5,000,000 shares authorized		
Common stock, par value \$0.01 per share, 80,000,000 shares authorized; 36,028,682 and 35,948,108 shares issued and 28,283,175 and 29,584,436 shares outstanding, respectively	361	360
Additional paid-in-capital	187,041	184,856
Accumulated deficit	(85,625)	(102,457)
Accumulated other comprehensive income	(2,677)	(1,834)
Treasury stock at cost, 7,745,507 and 6,363,672 common shares, respectively	(10,668)	(5,668)
<b>Total stockholders' equity</b>	<b>88,432</b>	<b>75,257</b>
Total liabilities and stockholders' equity	\$ 120,344	\$ 107,231

See accompanying notes to unaudited consolidated financial statements.

**Table of Contents****HARVARD BIOSCIENCE, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS**

(unaudited, in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Revenues	\$ 26,453	\$ 20,998	\$ 78,658	\$ 58,119
Cost of product revenues	13,886	10,769	41,259	29,538
Gross profit	12,567	10,229	37,399	28,581
Sales and marketing expenses	4,101	2,836	12,100	7,896
General and administrative expenses	4,407	3,888	12,475	10,757
Research and development expenses	1,240	1,074	3,549	3,162
Restructuring charges	283	59	283	508
Amortization of intangible assets	593	442	1,702	1,172
Total operating expenses	10,624	8,299	30,109	23,495
Operating income	1,943	1,930	7,290	5,086
Other income (expense):				
Gain from adjustment of acquisition contingencies			429	
Foreign exchange	(2)		(109)	(299)
Interest expense	(196)	(60)	(479)	(139)
Interest income	11	5	60	18
Other, net	(193)	(391)	(310)	(393)
Other expense, net	(380)	(446)	(409)	(813)
Income before income taxes	1,563	1,484	6,881	4,273
Income tax (benefit) expense	(11,167)	163	(9,951)	832
Net income	\$ 12,730	\$ 1,321	\$ 16,832	\$ 3,441
Income per share:				
Basic earnings per common share	\$ 0.45	\$ 0.04	\$ 0.58	\$ 0.12
Diluted earnings per common share	\$ 0.44	\$ 0.04	\$ 0.57	\$ 0.11
Weighted average common shares:				
Basic	28,443	29,467	29,197	29,691
Diluted	28,786	29,942	29,586	29,960

See accompanying notes to unaudited consolidated financial statements.

**Table of Contents****HARVARD BIOSCIENCE, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS****(unaudited, in thousands)**

	<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
<b>Cash flows from operating activities:</b>		
Net income	\$ 16,832	\$ 3,441
<b>Adjustments to reconcile net income to net cash provided by operating activities:</b>		
Stock compensation expense	1,992	1,687
Depreciation	898	892
Gain on acquisition contingencies	(429)	
(Gain) loss on sales of fixed assets	(9)	3
Restructuring charges		230
Amortization of catalog costs	256	243
Provision for allowance for doubtful accounts	(30)	(11)
Amortization of intangible assets	1,702	1,172
Amortization of deferred financing costs	67	34
Deferred income taxes	(11,031)	(53)
<b>Changes in operating assets and liabilities:</b>		
Decrease in accounts receivable	550	3,386
Increase in inventories	(1,406)	(941)
(Increase) decrease in other receivables and other assets	(261)	996
Decrease in trade accounts payable	(193)	(1,597)
Increase (decrease) in accrued income taxes payable	29	(193)
(Decrease) increase in accrued expenses	(547)	38
Decrease in deferred revenue	(20)	(112)
Decrease in other liabilities	(356)	(77)
<b>Net cash provided by operating activities</b>	<b>8,044</b>	<b>9,138</b>
<b>Cash flows used in investing activities:</b>		
Additions to property, plant and equipment	(615)	(820)
Additions to catalog costs	(376)	(135)
Proceeds from sales of property, plant and equipment	22	
Acquisitions, net of cash acquired	(6,115)	(12,812)
<b>Net cash used in investing activities</b>	<b>(7,084)</b>	<b>(13,767)</b>
<b>Cash flows used in financing activities:</b>		
Net proceeds from issuance of debt	10,350	9,000
Repayments of debt	(5,662)	(1,365)
Purchases of treasury stock	(5,000)	(2,404)
Net proceeds from issuance of common stock	194	112
<b>Net cash (used in) provided by financing activities</b>	<b>(118)</b>	<b>5,343</b>



Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Effect of exchange rate changes on cash	(213)	233
Increase in cash and cash equivalents	629	947
Cash and cash equivalents at the beginning of period	16,588	13,698
Cash and cash equivalents at the end of period	\$ 17,217	\$ 14,645
Supplemental disclosures of cash flow information:		
Cash paid for interest	\$ 453	\$ 88
Net cash paid for income taxes	\$ 2,036	\$ 1,059

See accompanying notes to unaudited consolidated financial statements.

---

**Table of Contents**

**HARVARD BIOSCIENCE, INC. AND SUBSIDIARIES**

**Notes to Unaudited Consolidated Financial Statements**

**1. Basis of Presentation and Summary of Significant Accounting Policies**

***Basis of Presentation***

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience, the Company, our or we ) as of September 30, 2010 and for the three and nine months ended September 30, 2010 and 2009 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ( SEC ). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles ( U.S. GAAP ) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2009 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, which was filed with the SEC on March 11, 2010.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2010, results of operations for the three and nine months ended September 30, 2010 and 2009 and cash flows for the nine months ended September 30, 2010 and 2009, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2010 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

***Summary of Significant Accounting Policies***

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company s Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on March 11, 2010, with the exception of stock-based compensation on restricted stock units as noted below.

***Stock-based Compensation***

We account for share-based payment awards in accordance with the provisions of FASB ASC 718, *Compensation Stock Compensation*, which requires us to recognize compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock units ( RSUs ) and employee stock purchases related to the Employee Stock Purchase Plan ( ESPP ). The Company issues new shares upon stock option exercises, upon the vesting of RSUs and under the Company s ESPP.

An RSU is a grant representing the right to receive a share of common stock upon vesting of the RSU and satisfaction of other conditions but for which no share of common stock is issued until the RSU vests and any other applicable conditions are satisfied. A holder of an RSU does not have any rights of a stockholder until the RSU vests and is converted to common stock. The fair value of RSUs are based on the market price of the Company s stock on the date of grant and are recorded as compensation expense ratably over the applicable service period, which is generally four years. Unvested RSUs are forfeited in the event of termination of employment or engagement with the Company.

Stock-based compensation expense for stock options recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and has been reduced for estimated forfeitures. We value stock-based payment awards at grant date using the Black-Scholes option-pricing model ( Black-Scholes model ). Our determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards and actual and projected employee stock option exercise behaviors.

**2. Recently Issued Accounting Pronouncements**

In October 2009, the FASB issued Accounting Standard Update ( ASU ) No. 2009-13 *Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements*. This ASU establishes the accounting and reporting guidance for arrangements including multiple revenue-generating activities. This ASU provides amendments to the criteria for separating deliverables, and measuring and allocating arrangement consideration to one or more units of accounting. The amendments in this ASU also establish a selling price hierarchy for determining the selling price of a deliverable. Significantly enhanced

**Table of Contents**

disclosures are also required to provide information about a vendor's multiple-deliverable revenue arrangements, including information about the nature and terms, significant deliverables, and its performance within arrangements. The amendments also require providing information about the significant judgments made and changes to those judgments and about how the application of the relative selling-price method affects the timing or amount of revenue recognition. The amendments in this ASU are effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010. Early application is permitted. We believe adoption of this new guidance will not have a material impact on our consolidated results of operations or financial position.

In January 2010, the FASB issued Accounting Standards Update No. 2010-06, *Improving Disclosures about Fair Value Measurements (Topic 820) Fair Value Measurements and Disclosures* (ASU 2010-06), to add additional disclosures about the different classes of assets and liabilities measured at fair value, the valuation techniques and inputs used, the activity in Level 3 fair value measurements, and the settlements relating to Level 3 measurements. The provisions of this update will be effective for us in fiscal years beginning after December 15, 2010, and for the interim periods within fiscal years with early adoption permitted. We believe the adoption of this new guidance will not have a material impact on our consolidated results of operations or financial position.

**3. Goodwill and Other Intangible Assets**

Intangible assets consist of the following:

	September 30, 2010		December 31, 2009		Weighted Average Life (a)
	(in thousands)				
	Gross	Accumulated Amortization	Gross	Accumulated Amortization	
<b>Amortizable intangible assets:</b>					
Existing technology	\$ 11,256	\$ (8,014)	\$ 11,234	\$ (7,525)	5.1 Years
Tradename	4,348	(897)	4,123	(689)	13.3 Years
Distribution agreement/customer relationships	18,562	(4,813)	17,884	(3,927)	12.6 Years
Patents	8	(6)	9	(5)	5.6 Years
Total amortizable intangible assets	\$ 34,174	\$ (13,730)	\$ 33,250	\$ (12,146)	
<b>Unamortizable intangible assets:</b>					
Goodwill	\$ 34,642		\$ 32,108		
Other indefinite lived intangible assets	1,285		1,301		
Total goodwill and other indefinite lived intangible assets	\$ 35,927		\$ 33,409		
Total intangible assets	\$ 70,101		\$ 66,659		

(a) Weighted average life is as of September 30, 2010.

The change in the carrying amount of goodwill for the nine months ended September 30, 2010 is as follows:

	(in thousands)
Balance at December 31, 2009	\$ 32,108
Goodwill arising from business combination	2,817
Effect of change in foreign currencies	(283)

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Balance at September 30, 2010

\$ 34,642

Intangible asset amortization expense was \$0.6 million and \$0.4 million for the three months ended September 30, 2010 and 2009, respectively. Intangible asset amortization expense was \$1.7 million and \$1.2 million for the nine months ended September 30, 2010 and 2009, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be \$2.4 million for the years ending December 31, 2010 and 2011, \$2.2 million for the year ending December 31, 2012, \$2.0 million for the year ending December 31, 2013 and \$1.8 million for the year ending December 31, 2014.

**Table of Contents****4. Inventories**

Inventories consist of the following:

	September 30, 2010	December 31, 2009
	(in thousands)	
Finished goods	\$ 7,232	\$ 7,116
Work in process	689	559
Raw materials	8,351	6,731
 Total	 \$ 16,272	 \$ 14,406

**5. Restructuring and Other Exit Costs****2010 Restructuring Plan**

During the third quarter of 2010, the management of Harvard Bioscience developed a plan to streamline its operations at Panlab, the Harvard Apparatus business in Spain. The plan included workforce reduction in all functions of the organization. During the third quarter of 2010, the Company recorded restructuring charges of approximately \$0.3 million, representing severance payments to employees. No charges are expected to be incurred beyond the third quarter of 2010 on this matter.

The restructuring charges related to the 2010 Restructuring Plan were as follows:

	Severance and Related Costs (in thousands)
Restructuring charges	\$ 283
Cash payments	(196)
 September 30, 2010 accrual balance	 \$ 87

**2009 Restructuring Plan**

During the quarter ended March 31, 2009, the management of Harvard Bioscience initiated a plan to relocate the Scie-Plas operation to Hoefer's San Francisco, California facility and exit its general fabrication business as part of its ongoing business improvement initiative. During the quarter ended June 30, 2009, Biochrom's management initiated a plan to improve Biochrom's manufacturing margins. The combined costs of these activities recorded in the year ended December 31, 2009 were \$0.7 million.

Aggregate restructuring charges relating to the 2010 Restructuring Plan and the 2009 Restructuring Plan were as follows:

	Three Months Ended September 30, 2010		Nine Months Ended September 30, 2009	
	(in thousands)		(in thousands)	
Restructuring charges	\$ 283	\$ 110	\$ 283	\$ 658

**6. Acquisitions**

***Coulbourn Instruments***

On August 23, 2010, the Company through its wholly-owned subsidiary, Denville Scientific, Inc. acquired substantially all of the assets of Coulbourn Instruments LLC (Coulbourn), a Delaware limited liability company with its principal offices in Pennsylvania.

During the third quarter of 2010, the Company paid approximately \$4.6 million to acquire essentially all of the assets of Coulbourn. The Company funded the acquisition from its existing cash balances and borrowings under its credit facility.

**Table of Contents**

Coulbourn Instruments is a manufacturer of behavioral measurement products, with a strong focus on systems for assessing learning and memory utilized in research laboratories. This acquisition is complementary to the Company's behavior research products, thereby strengthening the Company's position in this market.

We have preliminarily allocated the purchase price for the Coulbourn acquisition. The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible assets acquired as follows:

	<b>(in thousands)</b>
Tangible assets	\$ 796
Liabilities assumed	(234)
<b>Net assets assumed</b>	<b>562</b>
Goodwill and intangible assets:	
Goodwill	2,817
Customer relationships	799
Trade name	225
Technology	219
Non-compete agreements	8
<b>Total goodwill and intangible assets</b>	<b>4,068</b>
<b>Acquisition purchase price</b>	<b>\$ 4,630</b>

Direct acquisition costs related to Coulbourn, recorded in other expense, net in our consolidated statement of operations, were \$0.2 million and \$0.3 million for the three and nine months ended September 30, 2010, respectively.

The results of operations for Coulbourn Instruments have been included in our consolidated financial statements from the date of acquisition. The financial results of this acquisition are considered immaterial for the purposes of proforma financial statement disclosures. Goodwill recorded as a result of acquisition of Coulbourn Instruments is deductible for tax purposes.

***Denville Scientific***

On September 2, 2009, the Company through its newly formed wholly-owned subsidiary, DAC Acquisition Holding, Inc., acquired substantially all of the assets of Denville Scientific, Inc. (Denville), a Delaware corporation with its principal offices in New Jersey.

Under the terms of the Asset Purchase Agreement, the Company made payments of approximately \$20.8 million in cash during 2009. The final payment of approximately \$1.5 million was paid in the second quarter of 2010. The Company funded the final installment of the purchase price from its existing cash balances and its credit facility.

Denville is a supplier of molecular biology products, with a focus on liquid handling consumables utilized in research laboratories. We believe that the acquisition of Denville Scientific has brought to Harvard Bioscience a well-established business with an excellent organic growth history, an extensive field sales organization throughout the United States and a significant consumables business.

The amounts of Denville's revenue and net income included in the consolidated statement of operations for the three months ended September 30, 2010 are \$6.7 million and \$0.6 million, respectively. The amounts of Denville's revenue and net income included in the consolidated statement of operations for the nine months ended September 30, 2010 are \$18.9 million and \$1.5 million, respectively.

The following consolidated pro forma information is based on the assumption that the acquisition occurred on January 1, 2009. Accordingly, the historical results have been adjusted to reflect amortization expense and interest costs that would have been recognized on such a pro forma basis. The unaudited pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position



## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

or results of operations which would have been reported had we completed the acquisition during these periods or which might be reported in the future.

	<b>Three Months Ended September 30, 2009 (in thousands)</b>	<b>Nine Months Ended September 30, 2009 (in thousands)</b>
<b>Pro Forma</b>		
Revenues	\$ 25,465	\$ 73,685
Net income	\$ 2,090	\$ 4,872

**Table of Contents****7. Warranties**

Warranties are estimated and accrued for at the time sales are recorded. A rollforward of product warranties is as follows:

	<b>Beginning Balance</b>	<b>Payments</b>	<b>Additions</b>	<b>Ending Balance</b>
		(in thousands)		
Year ended December 31, 2009	\$ 186	(56)	32	\$ 162
Nine months ended September 30, 2010	\$ 162	(5)	(8)	\$ 149

**8. Comprehensive Income**

As of September 30, 2010, accumulated other comprehensive income consisted of cumulative foreign currency translation adjustments of \$0.1 million and, in accordance with FASB ASC 715-20, *Compensation Retirement Benefits, Defined Benefit Plans* \$(2.7) million to reflect the under-funded status of the Company's pension plans net of tax.

The components of total comprehensive income were as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>	<b>2010</b>	<b>2009</b>
	(in thousands)			
Net income	\$ 12,730	\$ 1,321	\$ 16,832	\$ 3,441
Other comprehensive income (loss)	2,693	(101)	(843)	2,323
Comprehensive income	\$ 15,423	\$ 1,220	\$ 15,989	\$ 5,764

Other comprehensive income for the three and nine months ended September 30, 2010 and 2009 consisted of foreign currency translation adjustments.

**9. Employee Benefit Plans**

Certain of the Company's United Kingdom subsidiaries, Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. The components of the Company's defined benefit pension expense were as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>	<b>2010</b>	<b>2009</b>
	(in thousands)			
<b>Components of net periodic benefit cost:</b>				
Service cost	\$ 48	\$ 43	\$ 136	\$ 113
Interest cost	209	237	587	617
Expected return on plan assets	(159)	(173)	(447)	(451)
Net amortization loss	40	32	113	80

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Net periodic benefit cost	\$ 138	\$ 139	\$ 389	\$ 359
---------------------------	--------	--------	--------	--------

For the three and nine months ended September 30, 2010, the Company contributed \$0.2 million and \$0.6 million, respectively, to its defined benefit plans. For the three and nine months ended September 30, 2009, the Company contributed \$0.1 million and \$0.3 million, respectively, to its defined benefit plans. The Company expects to contribute approximately \$0.2 million to its defined benefit plans during the fourth quarter of 2010.

**Table of Contents****10. Leases**

We have noncancelable operating leases for office and warehouse space expiring at various dates through 2017.

On May 22, 2010, we amended our lease agreement for our headquarters, office, light manufacturing and warehouse space in Holliston, Massachusetts. The amendment provides for an extended lease term commencing on June 1, 2010 and ending on May 31, 2017.

Rent expense, which is recorded on a straight-line basis, is estimated to be \$1.5 million for the year ending December 31, 2010. Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at September 30, 2010, are as follows:

	<b>Operating Leases</b>
	(in thousands)
2011	\$ 1,535
2012	1,397
2013	994
2014	709
2015	573
Thereafter	712
<b>Net minimum lease payments</b>	<b>\$ 5,920</b>

**11. Capital Stock***Stock Repurchase Program*

On December 6, 2007, the Board of Directors authorized the repurchase by the Company of up to \$10 million of its common stock in the open market or through privately negotiated transactions over the next 24 months. On November 3, 2009, the Board of Directors extended this program for an additional year. Under the program, shares could be repurchased from time to time and in such amounts as market conditions warrant, subject to regulatory considerations and any applicable contractual restrictions. During the three and nine months ended September 30, 2010, the Company repurchased in the open market 885,011 and 1,381,835 shares of common stock, respectively, at an aggregate cost of \$3.2 million and \$5.0 million, respectively, including commissions under the stock repurchase program. The share repurchases made in the third quarter of 2010 completed the \$10.0 million stock repurchase program.

During the three months ended September 30, 2009, the Company did not repurchase any common stock in the open market. During the nine months ended September 30, 2009, the Company repurchased in the open market 811,872 shares of common stock at an aggregate cost of \$2.4 million including commissions under the stock repurchase program.

Repurchased shares have been recorded as treasury stock and will be held until the Company's Board of Directors designates that these shares be retired or used for other purposes.

*Employee Stock Purchase Plan ( ESPP )*

In 2000, the Company approved the ESPP. Under the ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company's common stock. At the conclusion of the period, participating employees can purchase shares of the Company's common stock at 85% of the lower of the fair market value of the Company's common stock at the beginning or end of the period. Shares are issued under the plan for the six-month periods ending June 30 and December 31. Under this plan, 500,000 shares of common stock are authorized for issuance, of which 334,183 shares were issued as of September 30, 2010. During the three months ended September 30, 2010 and September 30, 2009, the Company did not issue any shares of the Company's common stock under the ESPP. For the nine months ended September 30, 2010 and September 30, 2009, the Company issued 24,689 shares and 19,717 shares respectively of the Company's common stock under the ESPP.

*Stock Option Plans*

We account for share-based payment awards in accordance with the provisions of FASB ASC 718, which requires us to recognize compensation expense for all share-based payment awards made to employees and directors including employee stock options, RSUs and employee stock purchases related to the ESPP.

On May 27, 2010, the Board of Directors approved the grant as of June 4, 2010 of 467,600 RSUs and 549,100 stock options under the Second Amended and Restated 2000 Stock Option and Incentive Plan (the 2000 Plan ). The RSUs were valued at the closing stock price on the date of grant. We utilized the Black-Scholes valuation model for estimating the fair value of the stock-based compensation.

**Table of Contents**

A summary of stock option and RSU activity under the 2000 Plan for the nine months ended September 30, 2010 is as follows:

	Stock Options			Restricted Stock Units	
	Available for Grant	Stock Options Outstanding	Weighted Average Exercise Price	Restricted Stock Units Outstanding	Grant Date Fair Value
Balance at December 31, 2009	946,729	7,502,235	\$ 4.45		\$
Granted	(1,106,700)	639,100	3.60	467,600	3.61
Exercised		(55,885)	2.13		
Vested (RSUs)					
Cancelled / forfeited	246,750	(246,750)	4.16		
Balance at September 30, 2010	86,779	7,838,700	\$ 4.40	467,600	\$ 3.61

The following assumptions were used to estimate the fair value of the stock options and the RSUs:

	Three Months Ended		Nine Months Ended	
	September 30, 2010	2009	September 30, 2010	2009
Volatility	55.19%	62.40%	56.02%	62.90%
Risk-free interest rate	1.86%	2.70%	2.25%	2.51%
Expected holding period	6.08	6.22	6.14	6.27
Dividend Yield	0%	0%	0%	0%

The weighted average fair values of the options granted under the 2000 Plan during the nine months ended September 30, 2010 was \$1.96, using the Black Scholes option-pricing model.

We used historical volatility to estimate the expected stock price volatility assumption. Historical volatility was determined by calculating the mean reversion of the daily-adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk free) appropriate for the term of the Company's employee stock options. The expected holding period of employee stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period is generally 4 years and the contractual life is 10 years.

Stock-based compensation expense for the three and nine months ended September 30, 2010 consisted of stock-based compensation expense related to employee stock options, RSUs and the ESPP. Stock-based compensation expense for the three and nine months ended September 30, 2009 consisted of stock-based compensation expense related to employee stock options and the ESPP.

Stock-based compensation expense for the three and nine months ended September 30, 2010 and 2009, respectively, was allocated as follows:

	Three Months Ended		Nine Months Ended	
	September 30, 2010	2009	September 30, 2010	2009
	(in thousands)			
Cost of sales	\$ 18	\$ 18	\$ 52	\$ 46
Sales and marketing	38	3	65	11
General and administrative	696	693	1,863	1,624

Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Research and development	7	3	12	6
Total stock-based compensation	\$ 759	\$ 717	\$ 1,992	\$ 1,687

We did not capitalize any stock-based compensation.

**Table of Contents***Weighted Average Common Shares Outstanding*

Basic income per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted net income per share assumes conversion of stock options and RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2010	2009	2010	2009
Basic	28,442,886	29,466,595	29,197,120	29,691,312
Effect of assumed conversion of employee and director stock options and restricted stock units	342,703	475,667	388,827	268,617
Diluted	28,785,589	29,942,262	29,585,947	29,959,929

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 6,143,904 and 5,570,223 shares of common stock for the three months ended September 30, 2010 and 2009, respectively, as the impact of these shares would be anti-dilutive. Excluded from the shares used in calculating the diluted earnings per common share in the above table are options to purchase approximately 5,931,044 and 5,000,273 shares of common stock for the nine months ended September 30, 2010 and 2009, respectively, as the impact of these shares would be anti-dilutive.

**12. Revolving Credit Facility**

During 2003, we entered into a \$20.0 million credit facility with Brown Brothers Harriman & Co. On December 1, 2006, we amended the terms of the credit facility extending the maturity date from January 1, 2007 to December 1, 2009.

On August 7, 2009, we entered into an amended and restated \$20.0 million revolving credit loan agreement with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The amended and restated revolving credit facility will mature on August 7, 2012. Borrowings under the credit facility bear interest at the London Interbank Offered Rate ( LIBOR ) plus 4.0%. At September 30, 2010, the interest rate for the facility was 4.26%. The amended and restated facility includes covenants relating to income, debt coverage and cash flow, as well as minimum working capital requirements. The credit facility also contains limitations on our ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of \$6.0 million and for acquisitions funded solely with equity in excess of \$10.0 million.

As of September 30, 2010 and December 31, 2009, we had \$18.0 million and \$13.3 million, respectively, outstanding under our credit facility. The borrowings under the credit facility were primarily related to our acquisitions of Denville Scientific and Coulbourn Instruments, and our stock repurchases. As of September 30, 2010, we were in compliance with all financial covenants contained in the credit facility; we were not subject to any borrowing restrictions under the financial covenants and had available borrowing capacity under our revolving credit facility of \$2.0 million.

**13. Income Tax**

As described in Note 13 in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, the Company had maintained a full valuation allowance against most of its United States deferred tax assets, net of deferred tax liabilities exclusive of deferred tax liabilities related to indefinite lived intangible assets. During the quarter ended September 30, 2010, management concluded that it is more likely than not that a majority of our U.S. deferred tax assets will be realized through future taxable income. This conclusion was based, in part, on our achieving sustained profitability in the U.S. Therefore, we released a significant portion of the valuation allowances related to these deferred tax assets. The release of the above mentioned valuation allowances resulted in an income tax benefit of \$11.3 million, which was recorded as a



discrete item during the quarter ended September 30, 2010.

**Table of Contents****14. Supplemental Cash Flow Information**

	<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
	(in thousands)	
Cash paid for acquisitions:		
Net assets acquired or liabilities assumed	\$ 562	\$ 3,818
Intangible assets	4,068	21,459
Final payment related to the acquisition of Denville Scientific	1,485	
Less contingent consideration		(12,465)
Cash paid for acquisitions	\$ 6,115	\$ 12,812

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.  
Forward Looking Statements**

*This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are principally, but not exclusively, contained in Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management's confidence or expectations, and our plans, objectives, expectations and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as may, will, should, could, would, expects, plans, anticipates, believes, goals, sees, estimates, projects, predicts, intends, think, potential, objectives, optimistic, strategy, and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include the Company's failure to identify potential acquisition candidates, successfully integrate acquired businesses or technologies, successfully negotiate favorable pricing and other terms with acquisition candidates to enable potential acquisitions to close, complete consolidations of business functions, expand our distribution channels, expand our product offerings, introduce new products or commercialize new technologies on a timely basis, including in the field of regenerative medicine, unanticipated costs relating to acquisitions, unanticipated costs arising in connection with the Company's consolidation of business functions and any restructuring initiatives, lack of demand or decreased demand for the Company's products due to changes in our customers' needs, success of our efforts with our distributor to promote sales of our microvolume spectrophotometer product and success of our strategies to increase the sales of other products, our ability to obtain regulatory approvals, including FDA approval, for our products including any products in the field of regenerative medicine, the current size or anticipated size of the regenerative medicine market, the existence and size of opportunities in the regenerative medicine market, our financial position, general economic outlook, or other circumstances, overall economic trends, the seasonal nature of purchasing in Europe, economic, political and other risks associated with international revenues and operations, the impact of the current economic and financial crisis, additional costs of complying with recent changes in regulatory rules applicable to public companies, our ability to manage our growth, our ability to retain key personnel, competition from our competitors, technological changes resulting in our products becoming obsolete, future changes to the operations or the activities of our subsidiaries due to manufacturing consolidations, our ability to meet the financial covenants contained in our credit facility, our ability to protect our intellectual property and operate without infringing on others' intellectual property, potential costs of any lawsuits to protect or enforce our intellectual property, economic and political conditions generally and those affecting pharmaceutical and biotechnology industries, research funding levels from endowments at our university customers, impact of any impairment of our goodwill or intangible assets, our acquisition of Genomic Solutions failing to qualify as a tax-free reorganization for federal tax purposes, our ability to utilize deferred tax assets after the release of our valuation allowances, the amount of earn-out consideration that the Company receives in connection with the disposition of the Company's Capital Equipment Business segment and factors that may impact the receipt of this consideration, such as the revenues of the businesses disposed of, plus factors described under the heading Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed with the SEC on March 11, 2010. Our results may also be affected by factors of which we are not currently aware. Also, these forward-looking statements represent our estimates*

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

*and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.*

---

## **Table of Contents**

### ***General***

Our strategy focuses on creating value through combining tuck-under acquisitions with organic growth and operational improvements. During the third quarter of 2010, we achieved organic revenue growth of 4.6% compared to the third quarter of 2009. One of the major drivers of our improved financial performance for the third quarter of 2010 was the acquisition of Denville. Denville was acquired in September 2009 and has been accretive to our earnings per share since the acquisition. In addition to Denville's positive impact on the third quarter, the core business also performed well. Our strong organic growth was achieved despite some weakness at our Hoefer and Harvard Apparatus Spain and U.K. subsidiaries.

The main drivers of organic revenue growth in the third quarter of 2010 were a general strengthening in our markets, new product development and the expansion of our sales force. During the second quarter of 2010, we launched the third of what we believe are four major new research syringe pumps in the Harvard Apparatus business. Syringe pumps are our single biggest product line. We believe that Pump 11 Elite is a major upgrade to our best selling Pump 11 product line, as it incorporates a color touch screen user interface, methods storage and programming without a separate computer and USB connectivity. In October 2010, we launched the fourth major new pump, called the KDS 100 Legato. We believe that the new KDS pump will bring similar improvements to the KD Scientific product line as the new Pump 11 Elite brings to the Harvard Apparatus line. We currently expect these new products to contribute to the organic growth at Harvard Apparatus, especially in the United States.

During the second quarter of 2010, we also launched what we believe is a major upgrade and expansion of our spectrophotometer product line at our Biochrom business. Spectrophotometry is our second biggest overall product line after syringe pumps. Spectrophotometry is the core of the Biochrom product line and this new product platform provides both improvements to the technical specifications, such as accuracy and reproducibility, as well as ease of use by adding a color touch screen user interface. In addition to our traditional strength in single beam spectrophotometers, we will now be adding dual beam instruments (which are inherently more accurate than single beam instruments) and variable bandwidth instruments, which provide significant extra flexibility to the user. With these new products, we intend to access a larger segment of the entire spectrophotometer market. Initial response from our distributors has been very positive. We think that these new products will help to drive organic growth during the remainder of 2010 and beyond.

In addition to driving growth in our core research markets, we have been investing in 2010 to create new products to address what we believe is a long term growth opportunity in the emerging field of regenerative medicine. Regenerative medicine is using stem cells to repair damaged organs and to grow organs outside the body for transplant. The US Department of Health and Human Services has projected that the US market for regenerative medicine may be \$100 billion in the coming years. The government's estimate appears to include the value of all regenerative medicine protocols and therapies, including potential cost savings versus current methodologies. Our strategy is not to become a therapeutics company but instead to provide tools to researchers and clinicians in the field of regenerative medicine. These new tools currently fall into two main categories: bioreactors for growing tissue and organs outside the body; and injectors for stem cell therapy. These new tools we are creating are being built on our existing technologies such as our market leading Harvard Apparatus precision syringe pumps and market leading Hugo-Sachs isolated organ systems.

Our first bioreactor is a product that was used to perform the world's first human transplant of a regenerated bronchus. Dr. Paolo Macchiarini et al reported this success in the Lancet in November 2008. During the second and the third quarter of 2010, we took orders for this product, making it what we believe is the world's first commercially available bioreactor that has been used to perform a human transplant of a regenerated organ. We believe it marks an important milestone in the development of the regenerative medicine field as the tools evolve from concepts to commercial quality products.

During the first half of 2010, one of our collaborators, Dr. Harald Ott at Massachusetts General Hospital (MGH) succeeded in regenerating a lung and subsequently transplanting it into a rat. In collaboration with Dr. Ott and MGH, we designed and developed a novel bioreactor that was used to grow the lung. The work was published online in Nature Medicine in July 2010. The bioreactor used by Dr. Ott was a modified version of one of our market leading Hugo-Sachs isolated organ systems.

In addition to the bioreactors described above, we also have started the development of a clinical version of one of our market leading Harvard Apparatus research syringe pumps. We anticipate that this pump will be used to inject cells into damaged tissue in cell therapy. The U.S. Food and Drug Administration has recently announced its intention to focus greater attention on the safety, particularly of the user interface, for clinical infusion pumps. We are still evaluating the effect of these new requirements and it is possible that complying with them will delay the submission of the new product for U.S. approval. However, we currently still anticipate launching our first clinical product during 2011.



## **Table of Contents**

We continue to pursue our tuck-under acquisition strategy.

We believe that through execution of our strategy of organic growth, tuck-under acquisitions and operational improvements we will be able to strengthen the Company and position ourselves well for when the economy recovers. While we expect the initiatives discussed above to positively impact our business, the success of these initiatives is subject to a number of factors, including fluctuations in foreign exchange rates, the current economic and financial condition and their impact on our customers and our ability to obtain credit on terms favorable to us, the competitiveness of our new products, the strength of our intellectual property underlying these products, the success of our marketing efforts and those of our distributors and the other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K filed with the SEC on March 11, 2010 and noted under "Item 1A. Risk Factors" below.

Our goal is to develop and sell products that improve life science research and regenerative medicine and as such, we monitor our operating metrics and when appropriate, effect organizational changes to leverage infrastructure and distribution channels. These changes may be effected as a result of various events, including acquisitions, the worldwide economy, general market conditions and personnel changes.

### ***Financing***

On August 7, 2009, we entered into an amended and restated \$20.0 million revolving credit loan agreement with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The amended and restated revolving credit facility will mature on August 7, 2012. Borrowings under the credit facility bear interest at LIBOR plus 4.0%. The facility includes covenants relating to income, debt coverage and cash flow, as well as minimum working capital requirements. The credit facility also contains limitations on our ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of \$6.0 million and for acquisitions funded solely with equity in excess of \$10.0 million.

At September 30, 2010, we had borrowings of \$18.0 million outstanding under our credit facility with Bank of America and Brown Brothers Harriman & Co.

Historically, we have funded acquisitions with debt, capital raised by issuing equity and cash flow from operations. In order to continue the acquisition portion of our growth strategy beyond what our current cash balances and cash flow from operations can support, we will need to raise more capital, either by incurring additional debt, issuing equity or a combination thereof.

### ***Components of Operating Income***

**Revenues.** We generate revenues by selling apparatus, instruments, devices and consumables through our catalog, our distributors, our direct sales force and our website. For products primarily priced under \$10,000, we typically distribute a new, comprehensive catalog every one to three years, initially in a series of bulk mailings, first to our existing customers, followed by mailings to targeted markets of potential customers. Over the life of the catalog, distribution will also be made periodically to potential and existing customers through direct mail and trade shows and in response to e-mail and telephone inquiries. From time to time, we also distribute catalog supplements that promote selected areas of our catalog or new products to targeted subsets of our customer base. Future editions of our comprehensive catalog and our catalog supplements will be timed at least in part with the incidence of new product introductions. Our end user customers are research scientists at pharmaceutical and biotechnology companies, universities and government laboratories. Revenue from catalog sales in any period is influenced by the amount of time elapsed since the last mailing of the catalog, the number of catalogs mailed and the number of new items included in the catalog. We launched our latest comprehensive catalog in March 2010, with approximately 850 pages, 11,000 products and approximately 65,000 copies printed. Revenues from direct sales to end users, derived through our catalog and the electronic version of our catalog on our website, represented approximately 25% and 30%, respectively, of our revenues for the nine months ended September 30, 2010 and for the year ended December 31, 2009.

Products sold under brand names of distributors, including GE Healthcare, are typically priced in the range of \$5,000-\$15,000. They are mainly scientific instruments like spectrophotometers and plate readers that analyze light to detect and quantify a very wide range of molecular and cellular processes or apparatus like gel electrophoresis units. We also use distributors for both our catalog products and our higher priced products, for sales in locations where we do not have subsidiaries or where we have distributors in place for acquired businesses. For the nine months ended September 30, 2010 and for the year ended December 31, 2009, approximately 42% and 48%, respectively, of our revenues were derived from sales to distributors.



---

## **Table of Contents**

For the nine months ended September 30, 2010, approximately 64% of our revenues were derived from products we manufacture; approximately 24% were derived from distributed products sold under our brand names and approximately 12% were derived from complementary products we distribute in order to provide the researcher with a single source for all equipment needed to conduct a particular experiment. For the year ended December 31, 2009, approximately 76% of our revenues were derived from products we manufacture; approximately 15% were derived from complementary products we distribute in order to provide the researcher with a single source for all equipment needed to conduct a particular experiment and 9% were derived from distributed products sold under our brand names.

For the nine months ended September 30, 2010 and for the year ended December 31, 2009, approximately 40% and 52%, respectively, of our revenues were derived from sales made by our non-U.S. operations. A large portion of our international sales during these periods consisted of sales to GE Healthcare, the distributor for our spectrophotometers and plate readers. GE Healthcare distributes these products to customers around the world, including to many customers in the United States, from its distribution center in Upsalla, Sweden. As a result, we believe our international sales would have been a lower percentage of our revenues if we had shipped our products directly to our end-users. Changes in the relative proportion of our revenue sources between catalog sales, direct sales and distribution sales are primarily the result of a different sales proportion of acquired companies.

*Cost of product revenues.* Cost of product revenues includes material, labor and manufacturing overhead costs, obsolescence charges, packaging costs, warranty costs, shipping costs and royalties. Our cost of product revenues may vary over time based on the mix of products sold. We sell products that we manufacture and products that we purchase from third parties. The products that we purchase from third parties have a higher cost of product revenues as a percent of revenue because the profit is effectively shared with the original manufacturer. We anticipate that our manufactured products will continue to have a lower cost of product revenues as a percentage of revenues as compared with the cost of non-manufactured products for the foreseeable future. Additionally, our cost of product revenues as a percent of product revenues will vary based on mix of direct to end user sales and distributor sales, mix by product line and mix by geography.

*Sales and marketing expenses.* Sales and marketing expense consists primarily of salaries and related expenses for personnel in sales, marketing and customer support functions. We also incur costs for travel, trade shows, demonstration equipment, public relations and marketing materials, consisting primarily of the printing and distribution of our catalogs, supplements and the maintenance of our websites. We may from time to time expand our marketing efforts by employing additional technical marketing specialists in an effort to increase sales of selected categories of products in our catalog. We may also from time to time expand our direct sales organizations in an effort to concentrate on key accounts or promote certain product lines.

*General and administrative expenses.* General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance, accounting, information technology and human relations functions. Other costs include professional fees for legal and accounting services, facility costs, investor relations, insurance and provision for doubtful accounts.

*Research and development expenses.* Research and development expense consists primarily of salaries and related expenses for personnel and spending to develop and enhance our products and to support collaboration agreements. Other research and development expense includes fees for consultants and outside service providers, and material costs for prototype and test units. We expense research and development costs as incurred. We believe that investment in product development is a competitive necessity and plan to continue to make these investments in order to realize the potential of new technologies that we develop, license or acquire for existing markets. Additionally, we are working to develop new products aimed at long term opportunities in the emerging field of regenerative medicine.

*Stock compensation expenses.* Stock-based compensation expense recognized under FASB ASC 718, *Compensation - Stock Compensation*, was \$0.8 million and \$2.0 million for the three and nine months ended September 30, 2010, respectively. Stock-based compensation expense recognized under FASB ASC 718 was \$0.7 million and \$1.7 million for the three and nine months ended September 30, 2009, respectively. This stock-based compensation expense was related to employee stock options, RSUs and the employee stock purchase plan and was recorded as a component of cost of product revenues, sales and marketing expenses, general and administrative expenses and research and development expenses.

### ***Income Taxes***

As described in Note 13 in our Company's Annual Report on Form 10-K for the year ended December 31, 2009, we have maintained a full valuation allowance against most of our United States deferred tax assets, net of deferred tax liabilities exclusive of deferred tax liabilities related to indefinite lived intangible assets. During the quarter ended September 30, 2010, management concluded that it is more likely than not that a majority of our U.S.





**Table of Contents**

deferred tax assets will be realized through future taxable income. This conclusion was based, in part, on our achieving sustained profitability in the U.S. Therefore, we released a significant portion of the valuation allowances related to these deferred tax assets. The release of the above mentioned valuation allowances results in an income tax benefit of \$11.3 million, which is being recorded as a discrete item during the quarter ended September 30, 2010. At September 30, 2010 our consolidated balance sheets reflected approximately \$9.9 million of deferred tax assets net of deferred tax liabilities. We currently expect the utilization of these net deferred tax assets to result in approximately \$9.9 million of cash savings over the next several years by offsetting future tax liabilities.

***Selected Results of Operations***

***Three months ended September 30, 2010 compared to three months ended September 30, 2009:***

	<b>Three Months Ended September 30,</b>		Dollar Change	%
	2010	2009		
	(dollars in thousands, unaudited)			
Revenues	\$ 26,453	\$ 20,998	\$ 5,455	26.0%
Cost of product revenues	13,886	10,769	3,117	28.9%
Gross margin percentage	47.5%	48.7%	N/A	-2.5%
Sales and marketing expenses	4,101	2,836	1,265	44.6%
General and administrative expenses	4,407	3,888	519	13.3%
Research and development expenses	1,240	1,074	166	15.5%

---

**Table of Contents***Revenues.*

Revenues increased \$5.5 million, or 26.0%, to \$26.5 million for the three months ended September 30, 2010 compared to \$21.0 million for the same period in 2009. Our Denville Scientific and Coulbourn Instruments subsidiaries, which were acquired on September 2, 2009 and August 22, 2010, respectively, contributed approximately \$5.2 million to the increase in the third quarter 2010 revenues. The effect of a stronger U.S. dollar decreased our third quarter revenues by \$0.7 million, or 3.3%, compared with the same period in 2009. Adjusting for the effects of foreign currency and acquisitions, revenues were up \$1.0 million, or 4.6%, year-to-year and reflected organic growth in our Harvard Apparatus and Biochrom businesses.

*Cost of product revenues.*

Cost of product revenues increased \$3.1 million, or 28.9%, to \$13.9 million for the three months ended September 30, 2010 compared with \$10.8 million for the three months ended September 30, 2009. The increase in cost of product revenues included \$3.2 million attributable to our Denville Scientific and Coulbourn Instruments subsidiaries, which was partially offset by a \$0.4 million favorable currency effect from a stronger U.S. dollar and the effects of cost reductions related to our operational improvement initiatives. Gross profit as a percentage of revenues decreased to 47.5% for the three months ended September 30, 2010 compared with 48.7% for the same period in 2009. The decrease in gross profit as a percentage of revenues was primarily due to the impact of Denville Scientific, which because it does not manufacture its products, has lower gross margins than our overall average margin. Third quarter 2010 gross margin as a percentage of revenues, excluding Denville, was 50.6% compared with 49.6% for the third quarter of 2009. The year-to-year quarterly increase reflected the effects of operational improvement initiatives completed during 2009, greater sales volume and a more favorable sales mix.

*Sales and marketing expense.*

Sales and marketing expenses increased \$1.3 million, or 44.6%, to \$4.1 million for the three months ended September 30, 2010 compared with \$2.8 million for the three months ended September 30, 2009. This increase was primarily due to our Denville Scientific and Coulbourn Instruments subsidiaries' costs of \$1.0 million and increased sales and marketing efforts in all of our businesses, which were partially offset by a \$0.1 million favorable impact of currency exchange rates.

*General and administrative expense.*

General and administrative expenses increased \$0.5 million, or 13.3% to \$4.4 million for the three months ended September 30, 2010 compared with \$3.9 million for the three months ended September 30, 2009. The year-to-year quarterly increase was primarily due to a \$0.3 million increase in the general and administrative expenses related to our Denville Scientific and Coulbourn Instruments subsidiaries.

*Research and development expense.*

Research and development expenses increased 15.5% to \$1.2 million for the three months ended September 30, 2010 compared with \$1.1 million for the same period in 2009, reflecting increased activity in our regenerative medicine initiative and new product development efforts in our Biochrom business.

*Amortization of intangible assets.*

Amortization of intangibles was \$0.6 million and \$0.4 million for the three months ended September 30, 2010 and 2009, respectively. The year-to-year quarterly increase in the amortization of intangible assets expenses was primarily due to the acquisition of Denville Scientific on September 2, 2009.

*Other income, net.*

Other expense, net, was \$0.4 million expense for the three month periods ended September 30, 2010 and 2009. Net interest expense was \$0.2 million for the three months ended September 30, 2010 compared to \$0.1 million for the three months ended September 30, 2009. The increase in net interest expense was primarily due to higher average debt balances in the third quarter of 2010 compared to the third quarter of 2009. Other income and expense, net, also included direct acquisition costs of \$0.2 million for the three months ended September 30, 2010 and \$0.4 million for the three months ended September 30, 2009.



**Table of Contents***Income taxes.*

Income tax benefit for the three months ended September 30, 2010 was approximately \$11.2 million. The income tax benefit was primarily due to the release of a significant portion of our valuation allowances related to our U.S. net deferred tax assets during the third quarter 2010. See Note 13 to our unaudited consolidated financial statements for additional detail. The income tax expense for the three months ended September 30, 2009 was approximately \$0.2 million. The effective income tax rate was 11.0% for the third quarter of 2009. The difference between our effective tax rate and the US statutory tax rate for the third quarter 2009 is principally attributable to the changes in our valuation allowance and our foreign rate differential.

*Restructuring*

During the third quarter of 2010, the management of Harvard Bioscience developed a plan to streamline our operations at Panlab, our Harvard Apparatus business in Spain. The plan included workforce reduction in all functions of the organization. During the third quarter of 2010, we recorded restructuring charges of approximately \$0.3 million, representing severance payments to employees. No charges are expected to be incurred beyond the third quarter of 2010 on this matter.

During the quarter ended March 31, 2009, the management of Harvard Bioscience initiated a plan to relocate the Scie-Plas operation to Hoefer's San Francisco location and exit the Scie-Plas general fabrication business as part of our ongoing business improvement initiative.

During the year ended December 31, 2009, we recorded restructuring charges in our Scie-Plas, Biochrom and Hoefer businesses related to the 2009 restructuring plan of approximately \$0.7 million. These charges were comprised of \$0.3 million in severance payments, \$0.2 million in inventory impairment charges related to the discontinuance of certain product lines (included in cost of product revenues) and \$0.2 million in various other costs.

No charges were recorded during the three months ended September 30, 2010 related to the 2009 restructuring plan. We recorded restructuring charges of \$0.1 million during the three months ended September 30, 2009, related to the 2009 restructuring plan.

*Nine months ended September 30, 2010 compared to nine months ended September 30, 2009:*

	<b>Nine Months Ended September 30,</b>		Dollar Change	% Change
	2010	2009		
	(dollars in thousands, unaudited)			
Revenues	\$ 78,658	\$ 58,119	\$ 20,539	35.3%
Cost of product revenues	41,259	29,538	11,721	39.7%
Gross margin percentage	47.5%	49.2%	N/A	-3.3%
Sales and marketing expenses	12,100	7,896	4,204	53.2%
General and administrative expenses	12,475	10,757	1,718	16.0%
Research and development expenses	3,549	3,162	387	12.2%

*Revenues.*

Revenues increased \$20.6 million, or 35.3%, to \$78.7 million for the nine months ended September 30, 2010 compared to \$58.1 million for the same period in 2009. Our Denville Scientific and Coulbourn Instruments subsidiaries contributed approximately \$17.4 million to the revenue increase in the nine months ended September 30, 2010. The effect of a stronger U.S. dollar decreased the Company's revenues by \$0.7 million, or 1.1%, compared with the same period in 2009. Adjusting for the effects of foreign currency and acquisitions, revenues were up \$3.9 million, or 6.5%, year-to-year and reflected organic growth across our Harvard Apparatus, Biochrom and Hoefer businesses.

*Cost of product revenues.*

Cost of product revenues increased \$11.7 million, or 39.7%, to \$41.2 million for the nine months ended September 30, 2010 compared with \$29.5 million for the nine months ended September 30, 2009. The increase in cost of product revenues included \$10.9 million attributable to our

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

Denville Scientific and Coulbourn Instruments acquisitions. A stronger U.S. dollar caused a \$0.3 million favorable currency effect on cost of product revenues for the nine months ended September 30, 2010. Gross profit as a percentage of revenues decreased to 47.5% for the nine months ended September 30, 2010 compared with 49.2% for the same period in 2009. The decrease in gross profit as a percentage of revenues was primarily due to the impact

---

**Table of Contents**

of Denville Scientific, which because it does not manufacture its products, has lower gross margins than our overall average margin. Gross margin as a percentage of revenues, excluding Denville, was 50.8% for the nine months ended September 30, 2010, and 49.5% for the nine months ended September 30, 2009. The year-to-year increase reflected the effects of operational improvement initiatives completed during 2009, greater sales volume and a more favorable sales mix compared with the same period in 2009.

*Sales and marketing expense.*

Sales and marketing expenses increased \$4.2 million, or 53.2%, to \$12.1 million for the nine months ended September 30, 2010 compared with \$7.9 million for the nine months ended September 30, 2009. This increase included \$3.3 million due to the acquisitions of our Denville Scientific and Coulbourn Instruments subsidiaries and reflected increased sales and marketing efforts across our businesses.

*General and administrative expense.*

General and administrative expenses increased \$1.7 million, or 16%, to \$12.5 million for the nine months ended September 30, 2010 compared with \$10.8 million for the nine months ended September 30, 2009. The year-to-year increase included \$0.7 million of expenses at our Denville Scientific subsidiary, \$0.1 million of expenses at our Coulbourn Instruments subsidiary, a \$0.2 million increase in stock compensation expense, and a \$0.7 million increase in other general and administrative areas.

*Research and development expense.*

Research and development expenses increased \$0.4 million, or 12.2%, to \$3.5 million for the nine months ended September 30, 2010 compared with \$3.1 million for the same period in 2009. The increase in research and development expenses was primarily due to \$0.2 million of spending related to regenerative medicine.

*Amortization of intangible assets.*

Amortization of intangibles was \$1.7 million and \$1.2 million for the nine months ended September 30, 2010 and 2009, respectively. The increase in the amortization of intangible assets expenses was primarily due to the acquisition of Denville Scientific on September 2, 2009.

*Other income, net.*

Other expense, net, was \$0.4 million and \$0.8 million expense for the nine month periods ended September 30, 2010 and 2009, respectively. Net interest expense was \$0.4 million for the nine months ended September 30, 2010 compared to net interest expense of \$0.1 million for the nine months ended September 30, 2009. The increase in net interest expense was primarily due to higher average debt balances in the nine months ended September 30, 2010 compared to the prior year period. Other income and expense, net, also included foreign exchange losses of \$0.1 million for the nine months ended September 30, 2010 and \$0.3 million for the nine months ended September 30, 2009. In the first three quarters of 2010, other income and expense, net, included a \$0.4 million gain from adjustment of the contingent consideration related to our Denville Scientific acquisition. Other income and expense, net, for the nine month periods ended September 30, 2010 and 2009, also included \$0.3 million and \$0.4 million, respectively, of direct acquisition costs.

*Income taxes.*

Income tax benefit for the nine months ended September 30, 2010 was approximately \$10.0 million. The income tax benefit was primarily due to the release of a significant portion of our valuation allowances related to our U.S. deferred tax assets during the third quarter 2010. See Note 13 to our unaudited consolidated financial statements for additional detail. The income tax expense for the nine months ended September 30, 2009 was approximately \$0.8 million. The effective income tax rate was 19.5% for the nine months ended September 30, 2009. The difference between our effective tax rate and the US statutory tax rate for the nine months ended September 30, 2009 is principally attributable to the changes in the valuation allowance and our foreign rate differential.

*Restructuring*

During the third quarter of 2010, the management of Harvard Bioscience developed a plan to streamline our operations at Panlab, our Harvard Apparatus business in Spain. The plan included workforce reduction in all functions of the organization. During the third quarter of 2010, we recorded restructuring charges of approximately \$0.3 million, representing severance payments to employees. No charges are expected to be incurred beyond the third quarter of 2010 on this matter.





## **Table of Contents**

During the quarter ended March 31, 2009, the management of Harvard Bioscience initiated a plan to relocate the Scie-Plas operation to Hoefers San Francisco location and exit the Scie-Plas general fabrication business as part of our ongoing business improvement initiative.

During the year ended December 31, 2009, we recorded restructuring charges in our Scie-Plas, Biochrom and Hoefers businesses related to the 2009 restructuring plan of approximately \$0.7 million. These charges were comprised of \$0.3 million in severance payments, \$0.2 million in inventory impairment charges related to the discontinuance of certain product lines (included in cost of product revenues) and \$0.2 million in various other costs.

No charges were recorded during the nine months ended September 30, 2010 related to the 2009 restructuring plan. We recorded restructuring charges of \$0.7 million during the nine months ended September 30, 2009, related to the 2009 restructuring plan.

### ***Microvolume Spectrophotometer Revenue***

One of our distributors has a contractual right to earn an exclusive license to the technology used in our microvolume spectrophotometer product for the term of its distribution agreement by purchasing a specified minimum quantity of that product during 2010. We believe that they will make sufficient purchases during 2010 to earn exclusivity and our revenues from those sales will be approximately \$5.0 million in 2010, approximately \$3.4 million of which was recorded as revenue during the first three quarters of 2010. The distributor will not have any contractual minimum purchase obligation in 2011 and beyond for that product. Based on information provided by the distributor, we believe that they are likely to have a high level of inventory of this product at December 31, 2010 and consequently sales of this product to them may be significantly lower in 2011 than in 2010. We have developed a plan with the distributor to promote sales of this product and have also developed strategies to increase sales of other products to offset the potentially lower sales of this product in 2011. In addition, we continuously monitor our cost structure in relation to revenue expectations and are evaluating our options in this regard.

### ***Liquidity and Capital Resources***

Historically, we have financed our business through cash provided by operating activities, the issuance of common stock and preferred stock, and bank borrowings. Our liquidity requirements have arisen primarily from investing activities, including funding of acquisitions, working capital and capital expenditures.

We ended the third quarter of 2010 with cash and cash equivalents of \$17.2 million compared to \$16.6 million at December 31, 2009. As of September 30, 2010 and December 31, 2009, the Company had \$18.0 million and \$13.3 million, respectively, of borrowings outstanding under its credit facility. Total debt, net of cash and cash equivalents, was \$0.8 million at September 30, 2010. Total cash and cash equivalents, net of debt was \$3.3 million at December 31, 2009.

**Table of Contents****Overview of Cash Flows**

(in thousands, unaudited)

	<b>Nine Months Ended September 30,</b>	
	<b>2010</b>	<b>2009</b>
<b>Cash flows from operations:</b>		
Net income	\$ 16,832	\$ 3,441
Changes in assets and liabilities	(2,204)	1,500
Other adjustments to operating cash flows	(6,584)	4,197
<b>Net cash provided by operating activities</b>	<b>8,044</b>	<b>9,138</b>
<b>Investing activities:</b>		
Acquisition, net of cash acquired	(6,115)	(12,812)
Other investing activities	(969)	(955)
<b>Net cash used in investing activities</b>	<b>(7,084)</b>	<b>(13,767)</b>
<b>Financing activities:</b>		
Net proceeds from issuance of debt	4,688	7,635
Purchases of treasury stock	(5,000)	(2,404)
Other financing activities	194	112
<b>Net cash (used in) provided by financing activities</b>	<b>(118)</b>	<b>5,343</b>
<b>Effect of exchange rate changes on cash</b>	<b>(213)</b>	<b>233</b>
<b>Increase in cash and cash equivalents</b>	<b>\$ 629</b>	<b>\$ 947</b>

Our operating activities generated cash of \$8.0 million for the nine months ended September 30, 2010 compared to \$9.1 million for the nine months ended September 30, 2009. The decrease in cash flows from operations was primarily due to changes in working capital year to year.

Our investing activities used cash of \$7.1 million during the nine months ended September 30, 2010 compared to \$13.8 million during the nine months ended September 30, 2009. Investing activities during both 2009 and 2010 included acquisitions, purchases of property, plant and equipment and expenditures for our catalogs. In August 2010, we acquired Coulbourn Instruments for approximately \$4.6 million which was funded from our existing cash balances and borrowings under our credit facility. During 2009, we acquired Denville Scientific for approximately \$22.3 million. The Denville purchase agreement required us to make the acquisition in three cash payments. We made the first cash payment of approximately \$12.8 million in the third quarter of 2009 and the second cash payment of approximately \$8.0 million in the fourth quarter of 2009. During the second quarter of 2010 we made the final payment of approximately \$1.5 million which is included in Acquisition, net of cash acquired under investing activities. During 2010, catalog costs reflect the publication and distribution of an 850-page Harvard Apparatus catalog. We spent \$0.6 million and \$0.8 million in the nine months ended September 30, 2010 and 2009, respectively, on capital expenditures. We currently expect to make approximately \$0.2 million of capital expenditures during the fourth quarter of 2010.

Our financing activities have historically consisted of borrowings and repayments under a revolving credit facility, long-term debt, the issuance of preferred stock and common stock, including the common stock issued in our initial public offering, and repurchases of our common stock under our stock repurchase program. During the nine months ended September 30, 2010, financing activities used cash of \$0.1 million. During the nine months ended September 30, 2010 we had net proceeds of debt of \$4.7 million and we repurchased in the open market 1.4 million shares of our common stock at a cost of \$5.0 million, including commissions. During the nine months ended September 30, 2009, we repurchased in the open market 0.8 million shares of our common stock at a cost of \$2.4 million, including commissions.

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

On August 7, 2009, we entered into an amended and restated \$20.0 million revolving credit loan agreement with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The amended and restated revolving credit facility will mature on August 7, 2012. Borrowings under the credit facility bear interest at LIBOR plus 4.0%. The facility includes covenants relating to income, debt coverage and cash flow, as well as minimum working capital requirements. The credit facility also contains limitations on our ability to incur additional indebtedness and requires lender approval for acquisitions funded with cash, promissory notes and/or other consideration in excess of \$6.0 million and for acquisitions funded solely with equity in excess of \$10.0 million.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary as a result of a number of factors. Based on our current operations and current operating plans, we expect that our available cash, cash generated from

**Table of Contents**

current operations and debt capacity will be sufficient to finance current operations and capital expenditures for 12 months and beyond. However, we may use substantial amounts of capital to accelerate product development or expand our sales and marketing activities. We may need to raise additional capital in order to make significant acquisitions. Additional capital raising activities will dilute the ownership interests of existing stockholders to the extent we raise capital by issuing equity securities and we cannot assure you that we will be successful in raising additional capital on favorable terms or at all.

**Impact of Foreign Currencies**

We sell our products in many countries and a substantial portion of our sales, costs and expenses are denominated in foreign currencies, especially the British pound sterling and the Euro.

Changes in foreign currency exchange rates resulted in reduction in revenues of \$0.7 million and expenses of \$0.6 million during the nine months ended September 30, 2010.

The loss associated with the translation of foreign equity into U.S. dollars was approximately \$0.8 million during the nine months ended September 30, 2010 compared to a gain associated with the translation of foreign equity into U.S. dollars of approximately \$2.3 million during the nine months ended September 30, 2009 (refer to note 8 to our unaudited consolidated financial statements). In addition, currency exchange rate fluctuations resulted in approximately \$0.1 million and \$0.3 million in foreign currency losses during the nine months ended September 30, 2010 and 2009, respectively.

As of September 30, 2010 and December 31, 2009, we had \$18.0 million and \$13.3 million, respectively, outstanding under our credit facility. The borrowings under our credit facility were primarily related to our acquisition of Denville Scientific and Coulbourn Instruments, and repurchases of our common stock under our stock repurchase program.

**Contractual Obligations**

The following schedule represents our contractual obligations, excluding interest, as of September 30, 2010.

	Total	2011	2012	2013	2014	2015	2016 and Beyond
	(in thousands)						
Bank credit facility and notes payable	\$ 18,000	\$	\$ 18,000	\$	\$	\$	\$
Operating leases	5,920	1,535	1,397	994	709	573	712
Capital leases, including imputed interest	1	1					
Total	\$ 23,921	\$ 1,536	\$ 19,397	\$ 994	\$ 709	\$ 573	\$ 712

**Critical Accounting Policies**

The critical accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Part II, Item 7 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on March 11, 2010.

**Recent Accounting Pronouncements**

In October 2009, the FASB issued ASU No. 2009-13 *Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements*. This ASU establishes the accounting and reporting guidance for arrangements including multiple revenue-generating activities. This ASU provides amendments to the criteria for separating deliverables, measuring and allocating arrangement consideration to one or more units of accounting. The amendments in this ASU also establish a selling price hierarchy for determining the selling price of a deliverable. Significantly enhanced disclosures are also required to provide information about a vendor's multiple-deliverable revenue arrangements, including information about the nature and terms, significant deliverables, and its performance within arrangements. The amendments also require providing information about the significant judgments made and changes to those judgments and about how the application of the relative selling-price method affects the timing or amount of revenue recognition. The amendments in this ASU are effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010. Early application is permitted. We believe adoption of this new

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

guidance will not have a material impact on our consolidated results of operations or financial position.

In January 2010, the FASB issued Accounting Standards Update No. 2010-06, *Improving Disclosures about Fair Value Measurements (Topic 820) Fair Value Measurements and Disclosures* (ASU 2010-06), to add additional disclosures about the different classes of assets and liabilities measured at fair value, the valuation techniques and inputs used, the activity in Level 3 fair value measurements, and the settlements relating to Level 3 measurements. The provisions of this

**Table of Contents**

update will be effective for us in fiscal years beginning after December 15, 2010, and for the interim periods within fiscal years with early adoption permitted. We believe the adoption of this new guidance will not have a material impact on our consolidated results of operations or financial position.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

The majority of our manufacturing and testing of products occurs in research centers in the United States, the United Kingdom, Germany and Spain. We sell our products globally through our direct catalog sales, direct sales force and indirect distributor channels. As a result, our financial results are affected by factors such as changes in foreign currency exchange rates and weak economic conditions in foreign markets.

We collect amounts representing a substantial portion of our revenues and pay amounts representing a substantial portion of our operating expenses in foreign currencies. As a result, changes in currency exchange rates from time to time may affect our operating results.

We are exposed to market risk from changes in interest rates primarily through our financing activities. As of September 30, 2010, we had \$18.0 million outstanding under our revolving credit facility, which bears interest at LIBOR plus 4.0%. At September 30, 2010, the interest rate on this debt was 4.26%. Assuming no other changes which would affect the margin of the interest rate under our revolving credit facility, the effect of interest rate fluctuations on outstanding borrowings under our revolving credit facility as of September 30, 2010 over the next twelve months is quantified and summarized as follows:

If compared to the rate as of September 30, 2010	Interest expense increase (in thousands)
Interest rates increase by 1%	180
Interest rates increase by 2%	360

**Item 4. Controls and Procedures.**

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

As required by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2010. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and our management necessarily was required to apply its judgment in evaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our Chief Executive Officer and Chief Financial Officer have concluded that they believe that our disclosure controls and procedures were effective, as of the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

We continue to review our internal controls over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business. These efforts have led to various changes in our internal controls over financial reporting. There were no changes in our internal controls over financial reporting that occurred during the third quarter ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents****PART II. OTHER INFORMATION****Item 1A. Risk Factors**

To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on March 11, 2010, except as follows:

As described in Management's Discussion and Analysis of Financial Condition and Results of Operations of this Quarterly Report on Form 10-Q, we believe that one of our distributors may end 2010 with a high inventory of our microvolume spectrophotometer product, and that we expect sales of that product to the distributor in 2011 to be significantly lower than in 2010. To the extent that our plans to promote sales of that product and increase the sales of other products or any future actions taken to address our cost structure in relation to our revenue expectations are not successful in offsetting the financial effect of any decrease in 2011 sales of our microvolume spectrophotometer product, there could be an adverse effect on our 2011 earnings.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

The following table provides information relating to the Company's purchases of its common stock during the three months ended September 30, 2010:

**ISSUER PURCHASES OF EQUITY SECURITIES**

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
July 1, 2010 - July 31, 2010	815,974	\$ 3.67	815,974	\$ 252,622
August 1, 2010 - August 31, 2010	69,037	\$ 3.66	69,037	
September 1, 2010 - September 30, 2010		\$		
Total	885,011	\$ 3.67	885,011	

On December 6, 2007, the Board of Directors authorized the repurchase by the Company of up to \$10.0 million of its common stock in the open market or through privately negotiated transactions over 24 months. Under the program, shares could be repurchased from time to time and in such amounts as market conditions warranted, subject to regulatory considerations and any applicable contractual restrictions. On November 3, 2009, the Board of Directors extended this program for an additional year. The share repurchases made in 2010 completed the \$10.0 million stock repurchase program.

During the life of the program, we repurchased in the open market 3,084,723 shares of common stock at an aggregate cost of \$10.0 million, including commissions under the stock repurchase program.

During the three and nine months ended September 30, 2010, the Company repurchased in the open market 885,011 and 1,381,835 shares of common stock, respectively, at an aggregate cost of \$3.2 million and \$5.0 million, respectively, including commissions under the stock repurchase program.

## Edgar Filing: HARVARD BIOSCIENCE INC - Form 10-Q

During the three months ended September 30, 2009, the Company did not repurchase any common stock in the open market. During the nine months ended September 30, 2009, the Company repurchased in the open market 811,872 shares of common stock at an aggregate cost of \$2.4 million including commissions under the stock repurchase program

### Item 6. Exhibits

#### Exhibit Index

31.1+	Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2+	Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

+ Filed herewith.

\* This certification shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

Date: November 5, 2010

HARVARD BIOSCIENCE, INC.

By: /s/ CHANE GRAZIANO  
**Chane Graziano**  
**Chief Executive Officer**

By: /s/ THOMAS MCNAUGHTON  
**Thomas McNaughton**  
**Chief Financial Officer**